This clearance applies to lung and cardiac imaging in patients with viral infection.
Fujifilm Healthcare announced Thursday it has captured 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its entire Sonosite point-of-care ultrasound (POCUS) system to be used for lung and cardiac imaging with patients who have COVID-19 infection.
Simultaneously, the company announced it has released a comprehensive user guide that can help providers use their POCUS technology to more easily and accurately recognize findings associated with COVID-19 that are related to lung and cardiac conditions.
“POCUS has emerged as a critical tool to support clinicians in their tireless efforts to evaluate lung and cardiac complications to COVID-19,” said Diku Mandavia, M.D., FACEP, FRCPC, senior vice president and chief medical officer of Fujifilm Sonosite, Inc.
According to Vi Dinh, M.D., an emergency medicine and critical care physician at Loma Linda University Medical Center who has used the system, it can play a vital role in the timely delivery of care.
“COVID-19 patients can deteriorate rapidly in a matter of minutes to hours, and ultrasound is there and ready when we don’t have minutes to spare,” he said. “And, while ultrasound alone doesn’t tell me exactly what the disease is, it allows me to look for typical COVID-19 ultrasound findings, as well as asses the disease severity to determine the optimal management plan for the patient.”
In particular, he said, POCUS is not only faster to use, but it is also safer and easier to sanitize during a pandemic.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.